Progress of the Asia-Pacific Medtech Innovation Forum(Singapore) and FDA STeP | |
---|---|
- The Asia-Pacific Medtech Innovation
Forum(Singapore, September) We participated in the Asia-Pacific Medtech
Innovation Forum event of Medtech, a global medical device consulting and
accelerator company, at Suntec Convention & Exhibiton Centre in Singapore
from September 26th to 27th. Although we were not selected for this competition
program, we are invited by Medtech and global major companies are members, participating
in several major companies, and exhibiting innovative medical device products
developed by start-up companies in the Asia-Pacific region. The Medtech Forum presented the startup companies'
No. 5 (1st stage: document screening, 2nd stage: 50 companies, 3rd stage: 20
companies, 4th stage: 4 companies, 5th stage: 1 company) to select the final
one (more than 100 million won in prize money), and the forum on accelerating
companies such as licensing, marketing, and production was displayed at the
same time. Many start-up companies participated to introduce
innovative technology products developed by start-up companies to a number of
major companies, but there was no opportunity to achieve their intended purpose
by participating in major companies' Singapore offices for business purposes.
The Singapore Institute of Technology (STUD), which highly evaluated our
technology, was asked to give a lecture on Anyfusion innovation technology
development design and experience to students in September 2023, and we decided
to negotiate the exclusive supply of Singapore with the introduction of buyer
who participated in the exhibition. - FDA STeP progress We officially submitted the application on August
26th, received the first supplement on September 25th after 30 days of
intensive review, and were asked to submit proofs of the safety of many
existing products by September 30th. Clinical trials were conducted at Seoul
National University, Yonsei University, Japan, and Samsung Seoul, and reported
to the academic community, and based on three SCi thesis data, we received
consulting from consulting company and submitted it on September 30th. With Anyfusion V100 and H100, clinical trial data
that we faithfully prepared for the Korea Health Industry Development Institute
(Ministry of Health and Welfare) support project, such as new product test
support project and clinical trial support project, have become important data
to efficiently use to prove FDA STeP's most important safety. - We will attend the Medical Japan International
Medical Device Exhibition in Tokyo, Japan, from October 11th to 14th. We are
scheduled to consult with Company N, one of Japan's leading global medical
device companies, and several other companies. Our low-cost, high-efficiency
Anyfusion ACP system is the most suitable and only general-purpose product for
advanced markets such as Japan and the United States, and we would like to
negotiate an exclusive supply contract with N company. Thank you. |
Next | Anyfusion has been granted Safer Technologies Program (STeP) designation |
---|---|
Prev | An exclusive supply contract with Kuwait company for Anyfusion ACPi System |